A lymph node biopsy can show whether swollen or abnormal lymph nodes are caused by cancer, infection, or an inflammatory condition like sarcoidosis. It’s one of the most definitive ways to distinguish between these possibilities because it lets pathologists examine the actual cells and tissue structure inside the node. Results typically come back within two to three days, though specialized testing can extend the timeline.
Cancer: Lymphoma and Metastatic Disease
The most common reason doctors order a lymph node biopsy is to check for cancer, either cancer that started in the lymph node itself (lymphoma) or cancer that spread there from somewhere else (metastatic disease).
For lymphoma, the biopsy reveals whether the abnormal cells are B cells or T cells, which is impossible to tell just by looking at cells under a standard microscope stain. Pathologists use a technique that tags specific proteins on cell surfaces to identify the cell type and how mature it is. This distinction matters because Hodgkin lymphoma, non-Hodgkin lymphoma, and the many subtypes within each category all require different treatment approaches. The biopsy can also detect genetic changes characteristic of specific lymphomas. Follicular lymphoma, for example, produces a recognizable overexpression of a protein that blocks normal cell death, while mantle cell lymphoma shows overproduction of a protein that drives cell division.
When cancer has spread to a lymph node from another organ, the biopsy helps identify where it originally started. Breast, lung, and oral cancers commonly show up in nearby lymph nodes. Pathologists can compare the gene activity patterns in the biopsy sample against known cancer types to match it to its origin. Knowing the primary site shapes the entire treatment plan.
Signs of Infection
A biopsy can identify the specific type of infection causing lymph node swelling, and different infections leave distinct cellular fingerprints.
Bacterial infections typically cause the node to fill with immune cells called neutrophils, the body’s first responders to bacteria. In more severe cases, the tissue breaks down into an abscess-like pattern with dead cells in the background. Cat scratch disease has its own hallmark: tiny pockets of pus surrounded by rings of inflamed tissue.
Viral infections look different. Epstein-Barr virus (the cause of mono) triggers the appearance of large, activated immune cells surrounded by plasma cells. Cytomegalovirus creates a similar picture but adds a distinctive feature: large cells with bright pink spots inside their nuclei that pathologists can identify on sight.
Tuberculosis produces a very specific pattern called caseating granulomas, clusters of immune cells with a characteristic core of dead tissue that has a cheese-like appearance. Pathologists also look for giant cells with multiple nuclei arranged in a horseshoe shape, a telltale sign of TB. Fungal infections can produce a similar granuloma pattern, which is why additional cultures or molecular tests are often run alongside the biopsy to confirm the exact organism.
Inflammatory and Autoimmune Conditions
Sarcoidosis is one of the most important non-cancer, non-infection diagnoses a lymph node biopsy can reveal. The hallmark finding is well-formed granulomas (tight clusters of immune cells) that are non-necrotic, meaning the tissue at the center is still alive. This distinguishes sarcoidosis from tuberculosis, where the granuloma centers are typically dead. Under the microscope, sarcoidosis granulomas show organized layers: a core of clustered immune cells and giant cells, surrounded by an outer ring of loosely arranged T cells.
Diagnosing sarcoidosis requires more than just seeing granulomas, though. The pathologist also needs to rule out infections and other causes of granulomatous inflammation. That’s why the biopsy is interpreted alongside your symptoms and other test results.
Benign and Reactive Results
Many lymph node biopsies come back showing no cancer or specific disease. The most common benign finding is reactive hyperplasia, which means the lymph node is simply doing its job, producing extra immune cells in response to a nearby infection or irritation. The key features that point toward a benign result include a preserved internal structure of the lymph node (pathologists call this “intact architecture”), no abnormal cell types invading the outer capsule, and no signs of cancer cells that migrated from elsewhere.
Another benign finding is sinus histiocytosis, where immune cells called histiocytes accumulate in the drainage channels of the node. This is a nonspecific reaction, essentially meaning the node is filtering actively but nothing dangerous is happening. If your report uses the term “reactive lymphadenopathy,” it generally means your lymph node was enlarged due to a normal immune response rather than a disease that needs treatment.
How Biopsy Type Affects Results
Not all biopsies provide the same level of information. There are three main approaches, and the choice affects how accurate the results are.
- Fine needle aspiration (FNA) uses a thin needle to suction out a small sample of cells. It’s the least invasive option, but it has a sensitivity of roughly 79% for detecting cancer in lymph nodes, meaning it misses about one in five cancers. FNA also can’t show the overall architecture of the node, which is critical for diagnosing lymphoma subtypes.
- Core needle biopsy removes a small cylinder of tissue, preserving some structural detail. Studies show sensitivity reaching 100% in controlled comparisons with FNA, with significantly better diagnostic accuracy.
- Excisional biopsy removes the entire lymph node. This provides the most complete picture and is generally preferred when lymphoma is suspected, since subtyping requires seeing the full tissue architecture.
Advanced Testing on Biopsy Samples
Beyond looking at cells under a microscope, pathologists can run molecular and genetic tests on the same biopsy tissue to refine a diagnosis or guide treatment decisions.
Gene sequencing panels now test for dozens of mutations simultaneously. Certain mutations serve as definitive diagnostic markers: one specific mutation is found in 100% of hairy cell leukemia cases, and another is present in nearly all cases of a rare lymphoma subtype called lymphoplasmacytic lymphoma. In cases where the tissue sample is limited or the cells look ambiguous under the microscope, gene sequencing identifies relevant mutations 70% of the time, more than double the rate of older genetic testing methods.
These molecular results also carry prognostic weight. Mutations in the TP53 gene, for instance, flag higher-risk disease across multiple types of B-cell lymphoma. Other mutations predict how well a cancer will respond to targeted therapies, making the biopsy not just a diagnostic tool but a guide for treatment planning.
Some biopsy samples are also tested for viral DNA within tumor cells. Epstein-Barr virus, for example, is found inside the cancer cells of certain aggressive lymphomas. When the virus is present in more than 80% of tumor cells in a patient without immune deficiency, it changes the classification of the lymphoma entirely.
Reading Your Pathology Report
A few terms show up frequently in lymph node biopsy reports that are worth understanding. “Architectural effacement” means the normal internal structure of the lymph node has been disrupted or destroyed, which can happen with large infections, granulomatous disease, or cancer. Effacement is a red flag that prompts further investigation. “Granulomatous inflammation” refers to those organized clusters of immune cells and can point toward TB, sarcoidosis, fungal infections, or other conditions depending on whether dead tissue is present at the center. “Atypical cells” means some cells look unusual but aren’t definitively cancerous, often triggering additional specialized staining or molecular tests.
Initial biopsy results generally arrive within two to three days. If your sample requires specialized staining, genetic sequencing, or consultation with additional pathologists, a preliminary report may be issued first with a note that a supplementary final report will follow. The full workup for complex lymphoma cases, including molecular profiling, can take one to two weeks.